Central Drugs Standard Control Organisation

The Central Drugs Standard Control Organisation (CDSCO) is the apex national regulator for pharmaceuticals, vaccines, blood products, medical devices and cosmetics in India, operating under the Directorate General of Health Services within the Ministry of Health and Family Welfare. Its statutory foundation rests on the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, supplemented by the Medical Devices Rules, 2017 and the New Drugs and Clinical Trials Rules, 2019. The organisation is headed by the Drugs Controller General of India (DCGI), who exercises the powers of the central licensing authority. The DCGI approves new drugs, fixes standards through the Indian Pharmacopoeia, regulates clinical trials, and grants licences for the import and manufacture of specified categories of drugs. India follows a system of dual regulation: the centre, through CDSCO, controls approval of new drugs, imports, and standard-setting, while the State Drug Controllers (State Licensing Authorities) license manufacture and sale of most drugs within their territories.

CDSCO's functional architecture comprises a head office at New Delhi, six zonal offices, four sub-zonal offices, multiple port offices and laboratories including the Central Drugs Laboratory (CDL), Kolkata, and the Central Drug Testing Laboratory network. Expert oversight is provided by the Drugs Technical Advisory Board (DTAB) and the Drugs Consultative Committee (DCC), both constituted under the 1940 Act, with DTAB being the highest technical body advising the central and state governments. The Subject Expert Committees (SECs) evaluate applications for new drugs and clinical trials. CDSCO is also the National Regulatory Authority (NRA) recognised by the World Health Organization for vaccine regulation, and the SUGAM online portal handles applications, approvals and licensing digitally.

In contemporary practice, CDSCO rose to prominence during the COVID-19 pandemic when it granted Emergency Use Authorisation to Covishield (Serum Institute) and Covaxin (Bharat Biotech) in January 2021, and later to other vaccines. It also coordinates risk-based inspections, post-market surveillance and the Pharmacovigilance Programme of India (PvPI) through the Indian Pharmacopoeia Commission, Ghaziabad. The October 2022 deaths in The Gambia linked to Indian-made cough syrups, and subsequent contamination episodes, intensified scrutiny of CDSCO's manufacturing oversight, prompting tightened export testing and revised Schedule M Good Manufacturing Practice norms notified in 2023–24. The proposed Drugs, Medical Devices and Cosmetics Bill, intended to replace the 1940 Act, seeks to modernise this framework, though as of 2026 the 1940 Act remains the governing statute.

For the UPSC Science & Technology and Governance segments of the Prelims and General Studies Paper III, CDSCO is tested on its parent ministry, statutory basis, the role of the DCGI, the dual centre-state regulatory model, and its function during vaccine approvals. Examiners frequently distinguish CDSCO from the Indian Pharmacopoeia Commission, NPPA (price control under the Drug Price Control Order), and ICMR. A typical question angle asks which authority grants Emergency Use Authorisation, or pairs regulatory bodies with their statutes, making precise recall of the 1940 Act and the 2019 Clinical Trials Rules essential.